Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account
Activity
RulesProposed and final rules open for commentGrantsFederal funding opportunities and deadlinesPress releasesWhat agencies are announcing publiclyHearingsCongressional committee hearings and meetingsBillsLegislation, actions, amendments, and votes
Views
AgenciesEverything from a single federal agencyTopicsActivity grouped by policy areaOrganizationsCompanies, associations, and advocacy groupsCommitteesHouse, Senate, and joint committee activityLegislatorsMembers of Congress, service, bills, and votes
Pricing
LoginCreate account

Table of contents

DetailsRelated

58 - Final SAP vp-vec-162-3107-e3-16-1-09

FDA-2022-N-2390-0656Supporting & Related Material
Document

Details

The document's own metadata, straight from the source system.

Title
58 - Final SAP vp-vec-162-3107-e3-16-1-09
Posted
May 20, 2026
Agency
Food and Drug Administration (FDA)
Topics
  • Pharmaceutical Policy
View on regulations.gov ↗
Related

Related documents

Other documents filed with this rulemaking.

View related documents
Other
C-26-457_Hogarth_notice_of_appearance
No comment periodJul 22, 2026
Other
Email C-26-457
No comment periodJul 22, 2026
Other
NEA
No comment periodJul 22, 2026
Other
C-26-457_Hughes_notice_of_appearance
No comment periodJul 22, 2026
Other
CDER_Opp_to_Motion_to_Modify_Final
No comment periodJul 22, 2026
Other
Sara_Rothman_NOA_-_revised
No comment periodJul 22, 2026
Other
C-26-457 FDA-2022-N-2390 Applicant Vanda motion re limited CDO modifications
No comment periodJul 22, 2026
Other
C-26-457.Vanda.CDC.ord(signed)
No comment periodJul 22, 2026

On this page

DetailsRelated
Government ContextGovernment Context

Track federal rulemaking documents, topics, and agencies — built on primary sources across the federal government.

ActivityRulesGrantsPress releases
ViewsAgenciesTopicsOrganizations
GuidesInstall Government ContextFive questions to ask your agentAll guides
CompanyAboutData sourcesPricing
LegalPrivacyTerms
© 2026 Government Context. Built on primary government sources.Not affiliated with any U.S. government agency.